Bottom Line: Universal germline genetic testing of nearly 40,000 patients with solid tumors detected a substantial proportion of inherited gene variants that would have been missed by the standard germline testing approach that excludes those over age 50.
Journal in Which the Study was Published: Cancer Discovery , a journal of the American Association for Cancer Research (AACR) .
Authors: Zsofia K. Stadler, MD , and Luis A. Diaz, Jr., MD, FAACR are the two co-corresponding authors. At Memorial Sloan Kettering Cancer Center Stadler serves as the clinical director of the Clinical Genetics Service, and Diaz is the head of Solid Tumor Oncology.
Background: Germline genetic screening can identify whether a patient with cancer has inherited genetic alterations in a gene or genes that are implicated in cancer. These inherited genetic alterations, known as germline pathogenic variants, can cause predispositions to cancer in people who carry them. Germline pathogenic variants can be used to flag cancer risk in patients’ family members, and the presence of certain germline pathogenic variants can also potentially guide patients’ treatments.
However, germline screening is typically performed on patients with cancer who are younger than 50 years old, explained Stadler.
She said that the logic for the age cutoff in germline screening is the assumption that patients with average- or late-onset cancers are less likely to have cancers caused by inherited pathologic variants than patients with early-onset cancers.
“The current standard practice is, in many ways, a gatekeeper for genetic testing. Our study aimed to assess how much inherited cancer risk we miss when we rely too heavily on age at diagnosis,” said Stadler. “As opposed to using an arbitrary cutoff such as age 50, we hypothesized that universal germline genetic testing would give us valuable insight into all patients regardless of age and potentially facilitate more testing for patients’ family members who may also carry hereditary cancer risk.”
How the Study was Conducted and Results: The research team performed germline genetic testing in all 39,184 patients with solid tumors, regardless of age, at the Memorial Sloan Kettering Cancer Center by using the MSK-Integrated Mutation Profiling of Actionable Targets (MSK-IMPACT) assay, which tested for 94 germline pathogenic variants using DNA isolated from patients’ blood or saliva.
Overall, 16.3% of all patients harbored at least one of these germline pathogenic variants. The researchers found that, if they had limited the number of patients who had pathogenic variants to those under age 50—the typical age cutoff for germline genetic sequencing—they would have excluded 4,601 patients with pathogenic variants (72% of all patients with pathogenic variants).
Stadler and colleagues also examined the prevalence of pathogenic variants across early-, average-, and late-onset cancers. Rather than using the standard definition of early-onset cancer as cancer that develops before age 50 regardless of cancer type, they classified patients’ cancer cases as either early-, average-, or late-onset based on the distribution of age at onset for each cancer type. They defined early-onset as occurring earlier than one standard deviation less than the cancer type’s mean age at onset; correspondingly, they defined late-onset as occurring greater than one standard deviation above the cancer type’s mean age at onset. Average-onset cancers were defined as occurring within one standard deviation of the mean age of onset for the cancer type.
Using this classification, they found that the prevalence of pathogenic variants was 18.4% among the early-onset population, 15.6% among the average-onset population, and 12.3% among the late-onset population.
High-penetrance pathogenic variants—variants that are more likely to produce the pathogenic effect with which they are associated—occurred in 9.1% of patients with early-onset cancers, 5.5% of those with average-onset cancers, and 2.6% of those with late-onset cancers. The prevalence of moderate-penetrance variants in patients with early-, average-, and late-onset cancers was 3.3%, 3.4%, and 2.5%, respectively. Taken together, high- and moderate-penetrance pathologic variants, which carry potential implications for cancer treatment strategies, occurred in about 9.7% of all patients, according to Stadler.
Authors’ Comments: The prevalence of pathogenic germline variants among older patients, especially high- and moderate-penetrance variants, suggested that a uniform cutoff for genetic screening at age 50 was insufficient, said Stadler. The study, she added, demonstrated the value of universal germline genetic testing, regardless of age.
“Hereditary cancer can occur at any age, and we should move toward a new standard in which genetic testing is considered for every patient diagnosed with cancer, regardless of age,” said Diaz. “Our manuscript shows that relying on age at diagnosis misses a substantial proportion of patients with germline pathogenic variants and provides strong support for moving toward universal germline genetic testing in patients with cancer.”
Doing so, Stadler added, would give clinicians insights into the patient’s cancer that could guide treatment, and it would also allow for a greater use of cascade testing: the process of testing the patient’s relatives to identify whether they might also harbor the same pathogenic variants.
“Unfortunately,” Stadler said, “cascade testing remains one of the most underused opportunities in cancer prevention. Once a hereditary cancer predisposition variant is identified in one patient, testing relatives becomes highly targeted and informative, yet only a minority of eligible relatives currently undergo testing.”
Study Limitations: A limitation of the study was that it was conducted at a single major tertiary cancer center. Additionally, certain cancers were over- or underrepresented, and the cohort was predominantly of European and Ashkenazi Jewish ancestry.
Funding & Disclosures: The study was funded by grants from the National Institutes of Health and Memorial Sloan Kettering Cancer Center.
Stadler discloses intellectual property rights in SOPHiA Genetics and serves as editor-in-chief for JCO Precision Oncology and as a section editor for UpToDate. Stadler also has an immediate family member who serves as cofounder, chief medical officer, and president for Blue Gen Therapeutics Foundation; the immediate family member also serves as a consultant in ophthalmology for Beacon Therapeutics and Regeneron Pharmaceuticals, Inc. outside the submitted work.
Diaz is a co-corresponding author of this study and serves as an editor-in-chief of Cancer Discovery ; in keeping with AACR editorial policy, a member of the Cancer Discovery editorial board managed the consideration process for this submission and independently rendered the final decision concerning acceptability. Diaz discloses membership on the board of directors of Quest Diagnostics and Epitope, and he acts as a consultant to Function Health, Grove Biopharma, Inc., Innovatus Capital Partners, Inc., Seer, Absci, DELFI Diagnostics, Inc., and NeoPhore. Diaz is listed as an inventor on several licensed patents regarding circulating tumor DNA analysis and mismatch repair deficiency technologies for diagnosis and therapy. Some of these roles may involve equity or royalty payments to inventors. Diaz’s spouse holds equity in Amgen.
# # #
Follow us: Cancer Research Catalyst ; Bluesky ; Facebook ; Instagram ; LinkedIn ; and X .
For AACR information, visit Fast Facts .
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 65,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 143 countries and territories around the world. Presently, 33% of members live outside the United States and 24% of AACR’s international members are located in countries building cancer research capacity. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting. The AACR publishes 10 prestigious, peer-reviewed scientific journals. Other AACR publications include Cancer Today, a magazine for cancer patients and caregivers; the annual AACR Cancer Progress Report; AACR Cancer Disparities Progress Report; AACR Annual Impact Report; Leading Discoveries, the AACR’s awareness and donor magazine; and the blog, Cancer Research Catalyst. In addition, the AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org .
Cancer Discovery
Universal germline genetic testing after a diagnosis of cancer
8-Oct-2026
The study was funded by grants from the National Institutes of Health and Memorial Sloan Kettering Cancer Center. Stadler discloses intellectual property rights in SOPHiA Genetics and serves as editor-in-chief for JCO Precision Oncology and as a section editor for UpToDate. Stadler also has an immediate family member who serves as cofounder, chief medical officer, and president for Blue Gen Therapeutics Foundation; the immediate family member also serves as a consultant in ophthalmology for Beacon Therapeutics and Regeneron Pharmaceuticals, Inc. outside the submitted work. Diaz is a co-corresponding author of this study and serves as an editor-in-chief of Cancer Discovery; in keeping with AACR editorial policy, a member of the Cancer Discovery editorial board managed the consideration process for this submission and independently rendered the final decision concerning acceptability. Diaz discloses membership on the board of directors of Quest Diagnostics and Epitope, and he acts as a consultant to Function Health, Grove Biopharma, Inc., Innovatus Capital Partners, Inc., Seer, Absci, DELFI Diagnostics, Inc., and NeoPhore. Diaz is listed as an inventor on several licensed patents regarding circulating tumor DNA analysis and mismatch repair deficiency technologies for diagnosis and therapy. Some of these roles may involve equity or royalty payments to inventors. Diaz’s spouse holds equity in Amgen.